scholarly journals Elevated serum ribonuclease in patients with pancreatic cancer.

1976 ◽  
Vol 73 (7) ◽  
pp. 2308-2310 ◽  
Author(s):  
K. K. Reddi ◽  
J. F. Holland
Keyword(s):  
Pancreatic Cancer ◽  
Elevated Serum ◽  
Serum Ribonuclease

scholarly journals Localized autoimmune pancreatitis mimicking pancreatic cancer: Case report and literature review

2018 ◽  
Vol 46 (4) ◽  
pp. 1657-1665 ◽  
Author(s):  
Wen-Ling Hsu ◽  
Shu-Min Chang ◽  
Pei-Yin Wu ◽  
Chin-Chuan Chang
Keyword(s):  
Pancreatic Cancer ◽  
Autoimmune Pancreatitis ◽  
Elevated Serum ◽  
Pancreatic Head ◽  
Corticosteroid Treatment ◽  
Cancer Case ◽  
Pancreatic Lesion ◽  
Immunoglobulin G4 ◽  
Positron Emission ◽  
Serum Igg4

Autoimmune pancreatitis (AP) is a rare autoimmune pancreatic manifestation of systemic immunoglobulin G4 (IgG4)-related sclerosing disease. Distinguishing between AP and pancreatic cancer is crucial because the clinical courses, treatments, and prognoses of these two disease entities are quite different. We herein report a case involving a 52-year-old man with subacute epigastralgia who visited our hospital for evaluation of a suspicious pancreatic mass found during esophagogastroduodenoscopy. Enhanced computed tomography (CT) revealed an enlarged lesion in the pancreatic head with encasement of hepatic vessels. The lesion also exhibited increased 18F-fluorodeoxyglucose accumulation on positron emission tomography/CT imaging, which was highly suggestive of pancreatic cancer. After open biopsy, morphologic examination showed an inflammatory infiltrate in the pancreas, which was compatible with chronic sclerotic pancreatitis. Further laboratory tests revealed an elevated serum IgG4 level, and the diagnosis of sclerotic pancreatitis was then confirmed. After corticosteroid treatment, the pancreatic lesion showed shrinkage on follow-up CT, and the serum IgG4 titer decreased to the normal range. This case suggests that clinicians should be familiar with the clinical presentations and diagnostic criteria of AP versus pancreatic cancer. An awareness of the differences between these diseases may avoid misdiagnosis and unnecessary surgical intervention.

Prospective trial for early detection of pancreatic cancer by elevated serum immunoreactive elastase

1990 ◽  
Vol 25 (6) ◽  
pp. 727-731 ◽  
Author(s):  
Tetuo Hayakawa ◽  
Takaharu Kondo ◽  
Tokimune Shibata ◽  
Motoji Kitagawa ◽  
Naoyuki Katada ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Detection ◽  
Prospective Trial ◽  
Elevated Serum ◽  
Immunoreactive Elastase

Clinical significance of serum alkaline phosphatase level in advanced pancreatic cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 183-183 ◽  
Author(s):  
I. Ohno ◽  
S. Mitsunaga ◽  
K. Nakachi ◽  
S. Shimizu ◽  
H. Takahashi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Prognostic Factor ◽  
Performance Status ◽  
Elevated Serum ◽  
Advanced Pancreatic Cancer ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Bile Stasis ◽  
Low Serum

183 Background: Alkaline phosphatase (ALP) is an enzyme that is elevated by various hepatobiliary diseases. Generally its elevation is thought to indicate bile stasis. There are some reports that show ALP is an important prognostic factor for several cancers such as colon, lung, and gastric cancer. Often it is speculated that ALP elevation indicates bile stasis caused by liver metastasis. However, the significance of ALP elevation in advanced pancreatic cancer (APC) patients is not well evaluated. The aim of this study was to determine the significance of elevated serum ALP as a prognostic factor in patients with APC even without jaundice and liver metastasis. Methods: Serum ALP levels were measured in 393 patients with APC receiving gemcitabine monotherapy before treatment, and according to those levels, patients were subgrouped (ALP<upper normal limit (UNL), UNL-500 U/L, 501-700 U/L, 701-1000 U/L, 1000U/L < ALP). The clinical data of each group were analyzed to see characteristics of elevated ALP patients. The relationship between ALP level and survival, response were also examined. Results: The elevated ALP group included poor performance status (PS>1) patients (41.3%, p=0.001), and associated with low serum albumin (3.31±0.38, p<0.01). The elevated ALP group (median survival time (MST) 112 days) showed significantly worse prognosis and lower disease control rate compared to the normal ALP group (MST 217days) (p<0.001, p<0.001). Multivariate analysis revealed ALP (p<0.001), CRP (p<0.001), ascites (p<0.001), distant metastasis (p=0.003), white blood cell count (p=0.005), PS (p=0.020), AST (p=0.020), and ALT (p=0.020) were independent prognostic factors. Similar results were seen in liver metastasis free patients without jaundice. Conclusions: Elevated serum ALP level correlated with poor performance status and low serum albumin. ALP was also the independent prognostic factor in liver metastasis free APC patients without jaundice. No significant financial relationships to disclose.

scholarly journals A Case of Pancreatic Cancer with Markedly Elevated Serum Immunoglobulin G4

2015 ◽  
Vol 20 (2) ◽  
pp. 78-82
Author(s):  
Young-Seok Kwon ◽  
Sung-Hoon Moon ◽  
Ho Suk Kang ◽  
Hyun Lim ◽  
Nan Young Choi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Elevated Serum ◽  
Serum Immunoglobulin ◽  
Immunoglobulin G4

scholarly journals Pancreatic Cancer With Ovarian Metastasis: Clinical Features, Diagnosis and Management

2020 ◽  
Author(s):  
Xingtong Zhou ◽  
Hongtao Cao ◽  
Banbo Zhao ◽  
Zhibo Zheng ◽  
Cheng Qin ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Features ◽  
Elevated Serum ◽  
Ovarian Metastasis ◽  
The Body ◽  
Ovarian Tumors ◽  
Pancreatic Tumors ◽  
Pancreatic Metastasis ◽  
Ovarian Metastases ◽  
Diagnosis And Management

Abstract Background: To summarize the clinical features, diagnosis and management of pancreatic cancer with ovarian metastasis.Methods: We retrospectively analyzed the clinical data of patients with ovarian metastases of primary pancreatic cancer who were admitted to our hospital from 01/01/1985 to 04/01/2020.Results: In total, there were 3757 female pancreatic-cancer patients. 9 of them were diagnosed with ovarian metastasis at an average age of 51.89 (38-69) years. The reason for the patients’ visit was generally a mass in the lower abdomen and/or abdominal pain. 7 patients had significantly higher serum CA19-9 levels. 8 patients had pancreatic tumors located in the body or tail; 1 patient, in the pancreatic head. All patients underwent excision of ovarian tumors and resection or biopsy of pancreatic tumors. 6 patients had pancreatic ductal adenocarcinoma (PDAC), 2 had pancreatic cystadenocarcinoma (PCC), and 1 had pancreatic neuroendocrine carcinoma (PNEC), all revealed by the pathological results. Ovarian tumors were assessed by pathology and were consistent with pancreatic metastasis. Currently, 2 patients are still alive (followed until 04/2020). The median survival time for all patients was 7 months (2.9-22 months).Conclusions: Pancreatic cancer with ovarian metastases is rare and easily misdiagnosed. When ovarian tumors are suspected to be metastatic, elevated serum CA19-9 may indicate that the primary cancer is pancreatic. Enhanced CT can facilitate diagnostic localization. In addition, if the pancreatic tumor cannot be removed, the ovarian tumor should still be resected to reduce the tumor load and improve quality of life.

Sign in / Sign up

Export Citation Format

Share Document